 |
|
|
| |
Simplification with fixed-dose tenofovir-emtricitabine or abacavir-lamivudine in adults with HIV infection: meta-analysis of two randomised, non-inferiority trials BICOMBO and STEAL
|
| |
| |
Reported by Jules Levin
12th EUROPEAN AIDS CONFERENCE/EACS. Cologne, Germany, November 2009
The full report of the data from the original presentations of these 2 studies:
STEAL Study: SIMPLIFICATION WITH FIXED-DOSE TENOFOVIR-EMTRICITABINE OR ABACAVIR ...
David A Cooper1, Mark Bloch2, Allison Humphries1, Janaki Amin1, David Baker3, Sean Emery1, Andrew Carr on behalf of the STEAL study group ...
www.natap.org/2009/CROI/croi_44.htm
IAS, Sydney 2007: Efficacy and safety of NRTI's switch to tenofovir plus emtricitabine (Truvada) vs. abacavir plus lamivudine (Kivexa) in patients with virologic suppression receiving a lamivudine containing HAART: The BICOMBO study - (07/30/06)
Amin J1; De Lazzari E2; Emery S1; Humphries A1; Martinez E2; Carr A3; Gatell J2; Cooper DA1
on behalf of the BICOMBO and STEAL study teams
1. National Centre in HIV Epidemiology and Clinical Research University of New South Wales,
Sydney, Australia
2. Hospital Clinic-IDBAPS- University of Barcelona, Barcelona, Spain
3. HIV, Immunology and Infectious Diseases Unit, St Vincent's Hospital, Sydney, Australia
|
| |
|
|
|
|
|
